News

Novo Nordisk is voluntarily recalling 1,468 product samples listed in the table below of Levemir®, Tresiba®, Fiasp®, Novolog® and Xultophy®, to the consumer level. These products are being ...
Levemir’s U.S. sales amounted to 1.27 billion Danish crowns ($185.6 million) in 2023, while Tresiba, Novo Nordisk’s other daily long-acting insulin, generated 1.33 billion crowns.
Novo Nordisk previously told USA TODAY it would discontinue U.S. sales of Levemir due to global manufacturing constraints and the availability of other forms of insulin.
Novo Nordisk will discontinue the Levemir FlexPens on April 1, 2024, and the ASHP says the injection pens are expected to be depleted that month.
Novo has another long-acting insulin, Tresiba, on the market. "Novo Nordisk will phase out, then permanently discontinue Levemir in the U.S. on December 31, 2024," the company said in a statement.
The drug’s maker, Novo Nordisk, announced in November that it was discontinuing Levemir Flexpen and Levemir subcutaneous injection solutions. Supply is expected to deplete by April, when tens of ...
Today we have some developments about Novo Nordisk’s insulin business, a side of the company that people don’t really talk about anymore, and some news about their GLP-1 business, a side that ...
Drug maker Novo Nordisk announced Tuesday the additional approval of Levemir (insulin detemir [rDNA origin]). The insulin already was approved for Type 1 diabetes in older children and adults and ...
Patients with type 2 diabetes are less likely to reach target blood sugar levels on Novo Nordisk's long-lasting insulin Levemir than on shorter-acting products, researchers said on Friday.
Levemir has already been approved for use in 37 countries and has been introduced in 11 European markets, with more launches expected in the second half. Novo Nordisk is planning a U.S. debut ...
Novo Nordisk will discontinue the Levemir FlexPens on April 1, 2024, and the ASHP says the injection pens are expected to be depleted that month.
Novo Nordisk will discontinue the Levemir FlexPens on April 1, 2024, and the ASHP says the injection pens are expected to be depleted that month.